Oramed Pharmaceuticals, Inc

Oramed Pharmaceuticals, Inc

ORMP

Get informed when a big investor buys or sells

+ Follow
Market Cap$190.72M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Oramed Pharmaceuticals, IncOramed Pharmaceuticals, Inc1.15.36%59%--
$0.98

Current Fair Value

79% downside

Overvalued by 79% based on the discounted cash flow analysis.

Share Statistics

Market cap$190.72 Million
Enterprise Value$177.91 Million
Dividend Yield$0.25 (5.36%)
Earnings per Share$1.53
Beta1.19
Outstanding Shares41,040,479

Return

Return on Equity58.63%ROE
Return on Assets58.86%
Return on Invested Capital25.49%

Valuation & Multiples

P/E Ratio1.1P/E Ratio
PEG0.23PEG
Price to Sales-Price to Sales
Price to Book Ratio0.78Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT2.28
Enterprise Value to Net Income0
Total Debt to Enterprise0.01
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 14, 2026
EPS Estimate
$0.15
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Next Earnings Call

Expected Date
November 12, 2026
EPS Estimate
$0.43
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls25,000▲ Infinity%
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %41.07%▲ 8.60%
Total Invested$81.07M▲ 80.09%
Investors Holding86▲ 22.00%

ESG Score

No data

About Oramed Pharmaceuticals, Inc

CEO: Nadav Kidron